NEW YORK (GenomeWeb News) - Arthur Holden plans to leave his post as vice president of corporate and market development at Illumina in mid-October, the company said this week in a filing with the US Securities and Exchange Commission.
 
Holden is director of the Serious Adverse Events Consortium, a pharma-backed initiative announced this week that aims to find genetic causes for severe adverse events that hamper drug development.
 

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

An artificial intelligence-based analysis suggests a third group of ancient hominins likely interbred with human ancestors, according to Popular Mechanics.

In Science this week: reduction in bee phylogenetic diversity, and more.

The New York Times Magazine looks into paleogenomics and how it is revising what's know about human history, but also possibly ignoring lessons learned by archaeologists.

The Economist reports on Synthorx's efforts to use expanded DNA bases they generated to develop a new cancer drug.